CGTN
8.2.2021 17:39:08 CET | Business Wire | Press release
Chinese President Xi Jinping has sent New Year's greetings to Chinese people of all ethnic groups, wishing happiness and good fortune for the people and prosperity for the nation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005631/en/
President Xi, also general secretary of the Communist Party of China Central Committee, extended the greetings during an inspection trip in southwest China's Guizhou Province prior to the Chinese New Year, which falls on February 12 this year.
"I'd like to extend Spring Festival blessings to people of all ethnic groups across the country. I wish everyone good health, happiness for their families, successful careers, and an auspicious Year of the Ox. I also wish our great motherland, with its beautiful mountains and rivers, much prosperity," Xi said.
During his trip, President Xi visited places including the city of Bijie and the provincial capital Guiyang, as well as a village, a residential community and a supermarket, from Wednesday to Friday.
His agenda also included a meeting with project leaders and core scientists of the Five-hundred-meter Aperture Spherical Radio Telescope (FAST) project in Guizhou. The FAST, held to be the world's most sensitive radio telescope, started operation on January 11, 2020.
On Friday's meet with scientists, President Xi called for a greater focus on scientific innovation and making it a driving force for China's development.
President Xi also spoke highly of the achievements made over the past year in Guizhou Province, as he heard a work report by the Guizhou Provincial CPC Committee and the provincial government on Friday.
He pointed out innovative development is an inevitable prerequisite of fostering China's new development paradigms and urged efforts to accelerate the integration of big data and the real economy and foster strategic merging industries.
More should be done to stimulate consumption demand and develop new consumption models, so as to unleash the consumption potential to the full, Xi said.
He demanded an effective transition from consolidating poverty alleviation achievements to promoting rural vitalization.
President Xi also expressed his great confidence in the future of the region, and wished it could make new achievements in the construction of ecological civilization.
A path of high-quality development that prioritizes ecology and highlights green development should be stuck, he added, adding that achieving common prosperity is one of the most important tasks of socialist modernization; and the government should support ethnic minorities in nurturing competitive industries and prospering their cultures.
He pointed out several aspects the government should work on to bring people benefits, including education, housing, employment, diseases prevention and control system as well as safe production.
Xi also stressed that the Red Army spent the longest time in Guizhou during the Long March, leaving behind precious spiritual treasures. And the Zunyi Conference, held in Zunyi City, is a crucial turning point in the Party's history.
The meeting focused on rectifying errors and established the correct leadership of the new Central Committee, as represented by Mao Zedong, Xi said, making it still matter today.
Original article:here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005631/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
